Use of MRI as an outcome measure in clinical trials in RA

被引：0
|
作者：
Annette H. M. van der Helm–van Mil
机构：
[1] Leiden University Medical Centre,Department of Rheumatology
来源：
Nature Reviews Rheumatology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Following a decade of substantial improvements in sensitivity and usability, MRI is increasingly used to assess primary outcomes of therapeutic trials in rheumatoid arthritis (RA). In the wake of an MRI-based evaluation of treatment efficacy, what lessons are emerging about the clinical value of this technique for patients with RA?
引用
收藏
页码：643 / 644
页数：1
相关论文
共 50 条
  • [21] Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
    Guptill, Jeffrey T.
    Benatar, Michael
    Granit, Volkan
    Habib, Ali A.
    Howard, James F.
    Barnett-Tapia, Carolina
    Nowak, Richard J.
    Lee, Ikjae
    Ruzhansky, Katherine
    Dimachkie, Mazen M.
    Cutter, Gary R.
    Kaminski, Henry J.
    NEUROLOGY, 2023, 101 (10) : 442 - 451
  • [22] Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia
    Sakinofsky, I
    Heila, H
    Krishnan, R
    SCHIZOPHRENIA BULLETIN, 2004, 30 (03) : 587 - 598
  • [23] HOW TO MEASURE OUTCOME IN CLINICAL TRIALS OF SUBSTANCE ABUSE TREATMENT
    Uchtenhagen, Ambros
    ADDICTION, 2012, 107 (04) : 720 - 722
  • [24] Visual acuity as an outcome measure in clinical trials of retinal diseases
    Beck, Roy W.
    Maguire, Maureen G.
    Bressler, Neil M.
    Glassman, Adam R.
    Lindblad, Anne S.
    Ferris, Frederick L.
    OPHTHALMOLOGY, 2007, 114 (10) : 1804 - 1809
  • [25] Quality of Life as an Outcome Measure for Epilepsy Clinical Trials.
    Joyce A. Cramer
    Pharmacy World and Science, 1997, 19 : 227 - 230
  • [26] ADDRESSING OUTCOME MEASURE VARIABILITY IN MYASTHENIA GRAVIS CLINICAL TRIALS
    Guptill, Jeffrey T.
    Granit, Volkan
    Habib, Ali
    Lee, Ikjae
    Ruzhansky, Katherine
    Howard, James F., Jr.
    Barnett-Tapia, Carolina
    Dimachkie, Mazen M.
    Nowak, Richard J.
    Kaminski, Henry J.
    Benatar, Michael
    MUSCLE & NERVE, 2022, 65 : S11 - S12
  • [27] ARTICULAR INDEXES FOR USE IN CLINICAL-TRIALS OF RA - REPLY
    THOMPSON, PW
    JOURNAL OF RHEUMATOLOGY, 1992, 19 (05) : 832 - 832
  • [28] Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials
    Cedarbaum, Jesse M.
    Jaros, Mark
    Hernandez, Chito
    Coley, Nicola
    Andrieu, Sandrine
    Grundman, Michael
    Vellas, Bruno
    ALZHEIMERS & DEMENTIA, 2013, 9 (01) : S45 - S55
  • [29] Use of the Cutaneous Lupus Disease Area and Severity Index as an outcome measure in clinical trials: a descriptive study
    Mack, E.
    Exton, L. S.
    Mohd Mustapa, M. F.
    McCourt, C.
    O'Kane, D.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (01) : 147 - 152
  • [30] Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease
    Jutten, Roos J.
    Papp, Kathryn, V
    Hendrix, Suzanne
    Ellison, Noel
    Langbaum, Jessica B.
    Donohue, Michael C.
    Hassenstab, Jason
    Maruff, Paul
    Rentz, Dorene M.
    Harrison, John
    Cummings, Jeffrey
    Scheltens, Philip
    Sikkes, Sietske A. M.
    ALZHEIMERS & DEMENTIA, 2023, 19 (02) : 708 - 720
12345